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ABSTRACT
Purpose To characterise a biorelevant simulated lung fluid
(SLF) based on the composition of human respiratory tract lining
fluid. SLF was compared to other media which have been uti-
lized as lung fluid simulants in terms of fluid structure, biocom-
patibility and performance in inhalation biopharmaceutical
assays.
Methods The structure of SLF was investigated using cryo-
transmission electronmicroscopy, photon correlation spectrosco-
py and Langmuir isotherms. Biocompatibility with A549 alveo-
lar epithelial cells was determined byMTT assay, morphometric
observations and transcriptomic analysis. Biopharmaceutical ap-
plicability was evaluated by measuring the solubility and dissolu-
tion of beclomethasone dipropionate (BDP) and fluticasone pro-
pionate (FP), in SLF.
Results SLF exhibited a colloidal structure, possessing vesicles
similar in nature to those found in lung fluid extracts. No adverse
effect on A549 cells was apparent after exposure to the SLF for
24 h, although somemetabolic changes were identified consistent
with the change of culture medium to a more lung-like compo-
sition. The solubility and dissolution of BDP and FP in SLF were
enhanced compared to Gamble’s solution.
Conclusion The SLF reported herein constitutes a biorelevant
synthetic simulant which is suitable to study biopharmaceutical
properties of inhalation medicines such as those being proposed
for an inhaled biopharmaceutics classification system.
KEY WORDS aerosol . beclomethasone dipropionate .
biopharmaceutics . dissolution . fluticasone propionate .
inhalation . solubility
ABBREVIATIONS
BDP Beclomethasone dipropionate
CCM Cell culture medium
DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
DPPG 1,2-dipalmitoyl-sn-glycerol-3-phosphot-rac(1-glycerol)
FDR False discovery rate
FP Fluticasone propionate
GO Gene ontology
HBBS Hank’s balanced salt solution
KEGG Kyoto Encyclopedia of Genes and Genomes
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide
pAcc The total perturbation accumulation
pORA The over-representation
pMDI Pressurised metered dose inhaler
RTLF Respiratory tract lining fluid
SDS Sodium dodecyl sulfate
SLF Simulant lung lining fluid
TEM Transmission electron microscopy
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INTRODUCTION
Drug solubility in lung fluid is an important determinant of
the fate of inhaled aerosol medicines. Persistence in the form
of a solid particle slows drug availability for target engage-
ment, systemic absorption or metabolism [1–4]. Particles that
dissolve slowly provide a sustained release mechanism, but are
also susceptible to mucociliary clearance [5] and uptake by
macrophages [6], or may lead to drug accumulation [7] or
toxicity [8]. These factors, together with recent interest in
developing a biopharmaceutical classification system for in-
haled medicines [9], have focused attention on drug solubility
in the lungs and the need to measure solubility in a medium
that is representative of human respiratory tract lining fluid
(RTLF). In contrast to intestinal fluid in which drug solubility
and dissolution has been investigated extensively [10], the
development of lung fluid simulants is in its infancy. Human
intestinal fluids have been characterised thoroughly in terms
of their composition and structure [11–13]. Simulants have
been designed to represent fed and fasted conditions [13,14],
studied for their biocompatibility [15] and made available as
commercial products [16].
When drug solubility or dissolution in the lungs has been
studied, the fluid used to represent RTLF has been water or
physiological salt solutions [17] (archetypically Gamble’s solu-
tion), often supplemented with phospholipids [18–20] or a
surfactant such as sodium dodecyl sulphate (SDS) [21,22].
Alternatively, products based on lung surfactant extracts such
as Survanta® or Curosurf® have been used [23]. The ten-
dency to refer to all these fluids as ‘simulated lung fluid’ re-
flects a confusion regarding how best to simulate RTLF in vitro.
Emerging data regarding the composition of healthy human
lung lining fluid in different regions of the lungs [24] provides
an opportunity to design a synthetic lung fluid that incorpo-
rates the major or critical components of the fluid that lines
the human lungs. For maximum utility, such a simulant
should be biocompatible with respiratory cells so that it can
be used in models to study lung-particle interactions in vitro.
The aim of this study was to characterize a synthetic simu-
lated lung fluid (SLF) that has been developed based on the
composition of human RTLF [25]. SLF was manufactured
and compared to other fluids which have been used as
simulants for RTLF in terms of structure and biocompatibility
with A549 alveolar epithelial cells and inhaled drug solubility
and dissolution.
MATERIAL AND METHODS
Materials
The 25 mg/mL stock solutions of 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC) and 1,2-dipalmitoyl-
sn-glycerol-3-phosphot-rac(1-glycerol) ammonium salt
(DPPG) were obtained from Avanti Polar Lipids, Inc.
(Alabama, USA). Reagent-grade purified human immu-
noglobulin (IgG), lyophilized human albumin, Bio-
reagent-grade transferrin, Sigma-grade cholesterol,
ascorbate, urate, certified reference material-grade glu-
tathione and Hank’s Balanced Salt Solution (HBSS)
were supplied by Sigma-Aldrich Company Limited
(Dorset, UK). HPLC-grade chloroform and water were
supplied by Fischer Chemicals (Loughborough, UK).
6α,9-Difluoro-17-[[(fluoromethyl)sulfanyl]carbonyl]-11β-
hydroxy-16α-methyl-3-oxo androsta-1,4-dien-17α-yl
propanoate (fluticasone propionate: FP) was purchased
from Adooq Bioscience (Irwin, CA), 9-Chloro-11β-hy-
droxy-16β-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl
dipropanoate (beclomethasone dipropionate; BDP) was
purchased f rom Medchem Expre s s (US ) , and
Survanta® from AbbVie Ltd. (UK).
Preparation of Simulated Lung Fluid (SLF)
The SLF was formulated to contain the most abundant
components of healthy human alveolar RTLF in the
concentrations that they manifest in vivo as determined
recently by Bicer [24] and was prepared as described
previously [25] (Table I). Briefly, to prepare the liposo-
mal content, 1.92 mL DPPC and 0.2 mL DPPG, from
25 mg/mL stock solutions in chloroform were combined
and 5 μL of cholesterol from a 200 mg/mL stock solu-
tion in chloroform was added. The mixture was stirred
gently in a round bottom flask and the chloroform
evaporated under streamed nitrogen gas, to produce a
thin layer of lipids at the base of the flask. The proteins
were added into the lipid flask in aliquots of aqueous
stock solutions: 4 mL of albumin (88 mg/mL), 4 mL of
IgG (26 mg/mL) and 1 mL of transferrin (15 mg/mL).
In order to represent lung antioxidant levels 88.5 μL of
the following antioxidant stock solutions were added:
10 mM ascorbate, 10 mM glutathione, and 5 mM urate
in the HPLC-grade water. The mixture was vortexed
Table I The Composition of Survanta and Simulated Lung Fluid (SLF)
Survanta® SLF
- Phospholipids 25 mg/mL
(including 11.0–15.5 mg/mL
disaturated phosphatidylcholine)
- Triglycerides 0.5–1.75 mg/mL
- Free fatty acids 1.4–3.5 mg/mL
- Protein less than 1.0 mg/mL
- DPPC 4.8 mg/mL
- DPPG 0.5 mg/mL
- Cholesterol 0.1 mg/mL
- Albumin 8.8 mg/mL
- IgG 2.6 mg/mL
- Transferrin 1.5 mg/mL
- Ascorbate 140 μM
- Urate 95 μM
- Glutathione 170 μM
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for 5 min, then gently mixed using a vibrating probe for
10 min at an amplitude of 10 to dissolve the lipids into
the solution. Finally, 10 μL of gentamicin was added,
followed by 775 μL of HBSS under gentle mixing.
Characterisation of the SLF
Cryo-transmission electron microscopy (cryo-TEM) of
SLF and Survanta was performed using a Zeiss Libra
120 Transmission Electron Microscope (Carl Zeiss NTS,
Oberkochen, Germany). The microscope operated at
80 kV in zero loss bright-field mode under cryo condi-
tions. Digital images were recorded under low dose con-
ditions, with a slow-scan CCD camera (TRS GmbH,
Moorenweis, Germany) and iTEM software (Olympus
Soft Imaging System GmbH, Münster, Germany). An
under focus of 1–2 μm was used to enhance the image
contrast. Thinly spread samples were prepared in a
100% humidity chamber to avoid dehydration, then
quickly vitrified in liquid ethane held at a temperature
just above its freezing point (−182°C). After vitrification,
the samples were transferred to the microscope using a
Gatan CT3500 cryo-transfer (Gatan, Oxon, UK), to
maintain samples below −165°C.
Photon correlation spectroscopy (Nanosizer, Malvern
Instruments, UK) at a scattered angle of 173° was used to
measure the hydrodynamic diameter of structures in SLF
and Survanta. Suspensions (1 mL) of both fluids were analysed
using instrument parameters: refractive index 1.330, temper-
ature 25°C, dynamic viscosity 0.8882 × 10−3 Pa s. Zetasizer
Software 6.20 was used to analyze the data.
A L a n gmu i r t r o u g h (Mod e l 6 0 2A ; N ima
Technologies Ltd., Coventry, UK) was used to make
surface pressure-area measurements at 23°C using a
PS4 surface pressure microbalance (0–240 mN/m
range, 0.1 mN/m resolution) fitted with a Wilhelmy
plate (1 cm width Whatman Grade 1 chromato-
graphic paper, GE Healthcare life sciences, Little
Chalfont, UK) and controlled by Nima IU4 computer
interface unit software. Suspensions of freeze dried SLF
and Survanta, 1 mg/mL, were prepared in chloroform,
vortexed for 10 min, then bath sonicated at 37 kHz,
25°C, for 10 min. For each isotherm, the test fluid
was deposited dropwise onto a 0.9% w/v NaCl sub-
phase surface using a Hamilton syringe and spreads
rapidly to cover the available area of the trough until
the surface pressure reached 20 mN/m, with the bar-
riers open at their maximum. The solvent was allowed
to evaporate for 10 min before the barriers were com-
pressed at 35 cm2/min. The mean molecular weights of
the surface-active components of SLF (38,760.9 g/mol)
and Survanta (843.5 g/mol) were calculated from their
defined compositions and together with the known
masses of the deposited monolayers, were used to deter-
mine the mean molecular area for each sample. The
isotonic saline subphase was used to simulate the influ-
ence of normal lung fluid counter-ions on the behavior
of the monolayer components [26].
Individual compressions were used to determine the
collapse pressure, which was 50 and 60 mN/m for SLF
and Survanta, respectively. Subsequently, each film was
compressed to a surface pressure 5 mN/m below their
collapse pressures and then expanded to reach the ini-
tial surface pressure, 20 mN/m. Triplicate experiments
of ten isotherm cycles were performed for each simulant
without an equilibration period between the expansion
and re-compression. Each individual compression-
expansion cycle took 10–25 min to complete. The de-
gree of hysteresis was determined from differences be-
tween the compression and expansion isotherms for
each cycle. The surface compressional modulus (K)
[27], was calculated using eq. 1:
K ¼ 1
C
¼ −A dΠ
dA
 
T
ð1Þ
where C is compressibility, A is the mean area per molecule
and dΠdA
 
T is the slope of the isotherm at a defined surface
pressure. Compressibility is characterized by high surface elas-
ticity and low interfacial stiffness [28]. K ranges between 12.5
and 50 mN/m for the liquid expanded phase, 50–100 mN/m
liquid intermediate phase and 100–250 mN/m for the liquid
condensed phase [29], whilst the condensed state has K
values >250 mN/m.
Biocompatibility with the Human A549 Cell Line
Human alveolar epithelial A549 cells (passage 38–46)
were cultured in a humidified atmosphere at 37°C,
5% CO2 using a cell culture medium (CCM) composed
of RPMI-1640 medium supplemented with 10% v/v fe-
tal bovine serum (FBS), 1% v/v L-glutamine and 0.1%
v/v gentamicin. For the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay A549 cells
were seeded in 96-well plates at 30,000 cells/cm2 using
reduced serum (2% FBS) CCM for 48 h before expo-
sure to SLF or Survanta for 24 h. After 24 h, cells were
washed with PBS and 200 μL of fresh CCM containing
50 μL of MTT solution (2.5 mg/mL in PBS) was added
to each well and the plate was incubated for 4 h in a
humidified incubator, after which the solution was
discarded. The cells were lysed and formazan crystals
formed were solubilised with 100 μL of a solution of
10% SDS in dimethylformamide:water (1:1). Cells were
incubated with lysis solution overnight at 37°C before
the absorbance of solubilised formazan was measured at
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570 nm using a SpectraMax microplate reader
(Molecular Devices, UK). SLF was non-toxic to A549
cells and was evaluated further using TEM and
transcriptomics.
For TEM, A549 cells on glass coverslips were fixed
using 2.5% (v/v) glutaraldehyde in 0.1 M phosphate
buffer for 2 h at 4°C. Following fixation the cells were
rinsed with 0.1 M phosphate buffer and treated with
1% (w/v) osmium tetroxide in 0.1 M phosphate buffer
(pH 7.3) for 20 min at 4°C. The coverslips were washed
for 10 min in phosphate buffer and dehydrated in a
graded ethanol dilution series 0 to 100%. Finally, the
cells were infiltrated with TAAB epoxy resin for 4 h at
room temperature. To section in the plane of the
monolayers, the coverslips were embedded in resin and
polymerized for 24 h at 70°C. Ultrathin sections (70–
90 nm) were prepared using a Reichert-Jung Ultracut E
ultramicrotome, mounted on 150 mesh copper grids,
contrasted using uranyl acetate and lead citrate, and
examined on an FEI Tecnai 12 transmission microscope
operated at 120 kV. Images were acquired with an
AMT 16000 M digital camera. Images (n ≥ 6 for each
sample) were acquired and analysed using ImageJ 1.47
software. Effects on cell health was assessed based on
morphometry; cellular, nuclear and mitochondrial area.
For transcriptomic analysis, RNA was isolated from
the A549 cells in 6-well plates (30,000 cells/cm2 in
2 mL CCM) after 24 h exposure to with SLF or
CCM (control). The cells were washed 3 times with
PBS, then lysed with RLT buffer (Qiagen). Total
RNA was isolated using an RNeasy mini kit (Qiagen)
following the manufactures guidelines. The RNA con-
centration was determined using a NanoDrop spectro-
photometer (NanoDrop Technologies, ThermoFisher,
USA). RNA integrity was analysed using the Agilent
2100 Bioanalyzer (Agilent Technologies). Only samples
demonstrating high RNA Integrity Number value (>9)
were qualified for microarray analysis.
RNA was amplified and labeled using the one-colour
Low Inpu t Qu i c kAmp Labe l i n g K i t (A g i l e n t
Technologies). Briefly, 200 ng of total RNA was reverse
transcribed into complementary DNA (cDNA) using a
T7-promoter primer and MMLV reverse transcriptase.
The cDNA was transcribed into complementary RNA
(cRNA), during which it was fluorescently labeled by
incorporation of cyanine(Cy)3-CTP. After purification
using the RNeasy mini kit (Qiagen), cRNA yield and
specific activity were determined using a NanoDrop
spectrophotometer. Only labeled cRNAs showing a spe-
cific activity above 8 pmol dye/μg RNA were analysed.
Labeled cRNA, 1.65 μg, was competitively hybridized
onto Whole Human Genome 4 x 44 K oligonucleotide
arrays (G4112F, Agilent Technologies) for 17 h in a
Tecan HS 4800 Pro Hybridization Station (Tecan
Benelux BVBA, Belgium). The arrays were scanned on
an Agilent G2565BA microarray scanner and further
processed using Agilent Feature Extraction Software
(version 10.7.3.1). Data processing steps used to gener-
ate the Agilent one-color output was performed as indi-
cated in the Agilent protocol GE1–107-Sep09. For each
feature (spot) on the array, gProcessedSignal (normalized
values for Cy3 fluorescence), feature quality and gene
information were analysed. Normalization included lin-
ear scaling and Quantile normalization; data were fil-
tered with regard to reliability including signal strength
(only features with signal values 3x the background stan-
dard deviation were considered valid features).
Solubility and Dissolution of Poorly Soluble Inhaled
Drugs
The solubility of fluticasone propionate (FP) and
beclomethasone dipropionate (BDP) was measured in
Gamble’s solution, SLF, Survanta and 0.5% sodium do-
decyl sulphate (SDS) by mixing excess drug powder (ap-
proximately 0.5 mg) with 0.5 mL of the solvent in a
microcentrifuge tube. The sealed tubes were vortex
mixed for 5 min before sonication at 37°C for 30 min
before transfer to a shaking water-bath at 37°C. After
48 h, the drug suspensions were centrifuged at
13000 rpm for 10 min, then the supernatant (0.2 mL)
was centrifuged for a second time before 0.1 mL of
supernatant was diluted 10 times with methanol. This
sample was analysed for drug concentration by HPLC.
For dissolution experiments Flixotide® 50 μg pMDI
or QVAR® 50 μg pMDI were actuated 10 times to
deliver aerosol to the surface of 0.45 μm pore polyester
membrane Transwell inserts (membrane pre-wetted with
dissolution medium) using a twin stage impinge as de-
scribed previously [30]. The inserts were transferred to
wells in 24-well base-plates containing 600 μL dissolu-
tion medium (Gambles solution, SLF, or water with
0.5% SDS). At intervals, the insert was moved to a
new well containing fresh dissolution medium. The drug
transferred to each receiver chamber was measured at
the end of the experiment using HPLC as described
previously [30]. The test was performed at room tem-
perature, with each result measured in triplicate.
RESULTS AND DISCUSSION
Characterisation of SLF
Uni-, bi-, and oligolamellar liposomes were visualised in
the SLF and Survanta using CryoTEM (Fig. 1a and b).
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The vesicles in SLF and Survanta samples had similar
appearance despite their different origins and process-
ing; SLF has a defined compositions and is fabricated
from defined individual components, whereas Survanta
is an enriched surfactant extract from bovine lungs.
Both fluids showed irregular electron-dense structures,
which may be protein aggregates. Dynamic light scatter-
ing also detected structures in the fluids; SLF showed a
strong signal for structures with a size of 57 nm corre-
sponding to the size of liposomes and a weaker signal
for 946 nm. Further interpretation was not possible due
to background scattering by multi-molecular protein ag-
glomerates, which is a recognized limitation of dynamic
light scattering size analysis in media with high protein
content [31].
Langmuir isotherms (pressure-area relationships) were
explored to determine whether the apparent similarities
in structures observed in the lung fluids extended to the
physicochemical behavior of monolayers formed on wa-
ter. The mean molecular area of SLF was greater than
that of Survanta (668–800 Å2 and 48–26 Å2, respective-
ly, over the 10 cycles), possibly due to the albumin
(which was present in SLF, but not Survanta) affecting
DPPC packing. SLF formed a stable monolayer after
the first compression-expansion cycle (Fig. 1b). During
compression it underwent transitions from a liquid ex-
panded to intermediate phase, followed by a liquid con-
densed phase. A large hysteresis loop and shift towards
lower molecular area was observed between the first
and second compression cycle. The isotherms of the
SLF Survanta
a
Cryo-TEM
of simulated
lung fluid
b
Langmuir
Isotherms
Compressibility
®Fig. 1 (a) CryoTEM.
Microstructures in synthetic lung
fluid (SLF) and Survanta®.
Microstructures imaged in the
suspension of SLF and Survanta
showing the presence of bilamellar
and oligolamellar liposomal vesicles.
(b) Isotherms. Isotherm cycles
and changes in compressibility
modulus over 10 consecutive
compressions for SLF and Survanta
films measured by Langmuir-
Blodgett trough.
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remaining cycles were identical indicating the formation
of a stable monolayer.
Three phase transitions were observed in the
Survanta isotherm during the first few cycles which dis-
appeared during the later cycles (Fig. 1b). At the initial
surface pressure (20 mN/m) Survanta formed an inter-
mediate phase (K < 100 mN/m), in which liquid ex-
panded and liquid condensed phases are assumed to co-
exist. Upon compression a plateau phase appeared at
around 47 mN/m, which occurred at progressively low-
er surface pressures over the course of subsequent cy-
cles, followed by an intermediate phase when further
compression was applied. Over the course of 10 cycles,
hysteresis occurred and the isotherm cycles underwent
an inward shift. The systematic shift of hysteresis loops
implied that there was an irreversible loss of material
from the surface due to the irreversible desorption into
the subphase over the course of a compression cycle.
The reduced hysteresis after the 7th cycle indicates the
formation of a stable monolayer at this point from
which no further loss of material occurred.
The reduction of Survanta compressibility observed
over the sequence of compression cycles has been re-
ported previously and attributed to the extrusion of hy-
drophobic proteins and associated lipids into the sub-
phase [32]. The hydrophobic SP-B and SP-C proteins
present in Survanta are thought to facilitate this extru-
sion, which is normally reversed upon expansion [33].
However, the speed at which the compression/
expansion cycles were repeated may have led to the
increasing hysteresis observed in the Survanta isotherms
because re-compression began before the monolayer had
completed re-spreading. Compared to Survanta, SLF
underwent the composition-refining process during the
first isotherm cycle when excess material was removed
from the interface during the first cycle, indicating a
simpler stable colloidal system. These data characterize
the structural and mechanical properties of RTLF
simulants which may affect drug solubility and dissolu-
tion. In vivo, a monolayer depleted in hydrophobic pro-
teins during breathing-cycle related compression will
show different wetting characteristics for drug particles
settling on its surface compared to the expanded system.
Thus the first stages of the particle dissolution process
will be affected by compression-dependent monolayer
composition, whereas changes in the micellar sub phase
will influence bulk solubility. In vitro, the lower stability
of the Survanta monolayer indicates a high propensity
to form micellar aggregates which are likely to sequester
poorly soluble drugs. In contrast, the stability of colloi-
dal structures in SLF make them less likely to sequester
drugs in micelles, however its high albumin content will
provide a reservoir for poorly-soluble compounds.
Biocompatibility of SLF
Survanta had a catastrophic effect on A549 cells in the
MTT assay, reducing viability by >90% after 24 h ex-
posure. In contrast, SLF and Gamble’s solution indicat-
ed mitochondrial activity comparable to that observed
in HBSS with cellular metabolism remaining within
20% of that in reduced-serum CCM control (data not
shown). The adverse effects of Survanta were mitigated
fully by dilution to 21% Survanta in HBSS (i.e.
Survanta diluted to match the phospholipid content of
SLF/human RLTF). The apparent biocompatibility of
SLF with A549 cells indicated by MTT assay was
followed up by exploring any morphometric or tran-
scriptional changes induced by exposure of A549 cells
to SLF.
TEM analysis following incubation of SLF with A549
cells revealed no effect compared to control on cellular,
nuclear and mitochondrial areas (Fig. 2). Nor were oth-
er morphological signs of cell distress observed, e.g. nu-
clear condensation, crescent shaped condensed chroma-
tin abnormal lamellar bodies or epithelial projections
(Fig. 2a). Interestingly, cytoplasmic and membrane-
bound vacuole inclusions (vacuoles at the apical surface
of the plasma membrane) were observed, which it is
tempting to attribute to uptake of DPPC liposomes fol-
lowing exposure to with SLF (Fig. 2b).
Using microarray analys is , 116 dif ferential ly
expressed genes (p < 0.05; 2 log-fold change in expres-
sion) were identified out of 10,705 genes with measured
expression. The data was analysed using iPathwayGuide
(Advaita Corporation, 2015) within the context of path-
ways in the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database and gene ontologies (GO) from the
Gene Ontology Consortium database. After correction
for the false discovery rate, 5 KEGG pathways were
found to be affected significantly (Table II). After elim
pruning to favour more significant terms, 5 GO terms
with a threshold above 10 genes per term were impact-
ed significantly (Table III). The perturbation (pAcc) pro-
vides a perturbation factor for each gene and the over-
representation (pORA) describes the probability of
changes to the number of genes affected in a certain
pathway (Fig. 3).
Pathway analysis showed that steroid biosynthesis, in-
cluding biosynthesis of cholesterol, steroid hormones and
vitamin D, was significantly induced. This was corrobo-
rated by the GO analysis which confirmed induction of
the cholesterol, sterol and steroid biosynthetic pathways
(p < 0.05). This may be the consequence of exogenous
cholesterol in SLF. An increase in oxidation-reduction
processes may also be related to the increase in choles-
terol synthesis, which involves many redox enzymes. As
Kumar et al.
Fig. 2 Morphological characterisation of A549 cells cultured in cell culture medium and SLF for 24 h. (a) Cell morphology. A549 control cells incubated with cell
culture medium (left) compared to A549 cell incubated with SLF (right). Scale bar: 2 μm. (b) Cellular uptake. SLF interaction with A549 cells indicated with arrows.
Scale bar: 500 nm (c) Cell dimensions. Culture medium compared to SLF showing no differences. Data represent mean ± sd, n = 6 images.
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many activators of the NfkB pathway are oxidants, the
observed up-regulation in the oxidative-reductive pro-
cess in this study might indicate that incubation with
SLF has immunomodulatory roles [34]. This would be
consistent with previous findings demonstrating that
DPPC can exert anti-inflammatory effects through the
inhibition of the NFkB-pathway [35]. Reduced DNA
replication was also identified robustly by pathway and
GO analysis, i.e. negative regulation of transcription
from RNA polymerase II promotor. This may be ex-
plained by the effect of change of culture environment
which stalls cell replication in vitro.
T a k e n t o g e t h e r , t h e MTT , mo rphome t r y
transcriptomic analyses demonstrate that SLF is biocom-
patible with A549 cells, though clearly further work will
be required to establish how robust this finding is across
cell lines and in primary cell models.
Solubility and Dissolution of FP and BDP in SLF
FP and BDP are poorly water soluble drugs, reported to have
concentrations of approximately 0.1–0.2 μg/mL in water
[9,36,37]. In Gamble’s solution, FP and BDP solubility was
0.7 and 1.0 μg/mL, respectively (Fig. 4). In surfactant-
containing media, the solubility of FP increased in the rank
order: SLF (2.0 μg/mL) < 0.5% SDS (13.1 μg/
mL) < Survanta (20.3 μg/mL). The BDP rank order of solu-
bility in the different media was changed, but BDP solubility
was higher than that of FP in each medium: SLF (16.8 μg/
mL), < Survanta (37.2 μg/mL) and <0.5% SDS (64.4 μg/
mL). Lung surfactants enhance the solubility of small, lipophil-
ic drug molecules, such as corticosteroids and cationic com-
pounds because they form structures with lipid domains
[38,39]. Unexpectedly, FP solubility in SLF was much closer
to that in Gamble’s solution than Survanta. Solubilisation
may be determined not only by lipid content but also the
interaction of components, including the drug, which affect
liposomal structures. For example, cholesterol may form tight
nanodomain complexes with DPPC stabilising the lamellar
structures formed [40], whereas albumin may solubilise the
cholesterol [41] and reduce the stability of the lamellar phase
and the extent to which drug is solubilised in such structures. A
recent review by Das et al. speculates how lung surfactant may
form different liquid crystalline phases with potential roles in
defining dissolution mechanism and rate [42].
The dissolution of FP and BDP aerosols from li-
cenced inhaler products correlated with drug solubility
in the dissolution medium. BDP dissolved more readily
Table II The Top (Strongest Signal) Pathways in Rank Order with their p-values: p-values in Bold Represent Significance
Pathway name Pathway id p-value p-value (FDR) p-value (Bonferroni)
Steroid biosynthesis 00100 2.599e-10 3.015e-8 3.015e-8
DNA replication 03030 1.493e-6 8.658e-5 1.732e-4
Terpenoid backbone biosynthesis 00900 5.547e-5 0.002 0.006
Metabolic pathways 01100 2.810e-4 0.008 0.033
Tryptophan metabolism 00380 0.002 0.038 0.191
Cell cycle 04110 0.002 0.040 0.240
Table III Top Gene Outology (GO) Terms and their p-values: p values in Bold Represent Significance
No pruning Elim pruning Weight pruning
GO Term p-value p-value
(FDR)
p-value
(Bonferroni)
GO Term p-value GO Term p-value
Sterol biosynthesis
process
2.000e-14 5.018e-11 5.018e-11 Cholesterol
biosynthesis process
1.900e-9 Sterol biosynthesis process 2.000e-14
Cholesterol
biosynthesis
process
2.300e-13 1.924e-10 5.771e-10 Negative regulation of
transcription from
RNA polymerase II promoter
0.008 Cell cycle phase transition 6.100e-5
Secondary
biosynthesis
process
2.300e-13 1.924e-10 5.771e-10 Oxidation-reduction process 0.013 Oxidation-reduction process 0.003
Steroid biosynthesis
process
1.400e-12 8.782e-10 3.513e-9 Sterol biosynthesis process 0.039 Negative regulation of
transcription from RNA
polymerase II promoter
0.008
Sterol metabolic
process
1.300e-10 6.523e-8 3.262e-7 Steroid biosynthesis process 0.044
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than FP and for both drugs the dissolution rate in SLF
was greater than in Gamble’s solution, but lower than
the rate in 0.5% SDS. An estimate for the solubility of
FP in the lungs using mechanistic modelling [43] ap-
pears to support the value obtained with SLF,
supporting the hypothesis that the salt solution is likely
to underestimate the dissolution of hydrophobic drugs,
while 0.5% SDS may overestimate solubility and hence
dissolution in the lungs. FP and BDP were selected to
represent inhaled drugs that have poor aqueous solubil-
ity and may be dissolution limited, accounting for their
relatively slow dissolution profiles which appear to con-
trast with the rapid onset of action that can be observed
for some inhaled molecules, e.g. many bronchodilators.
However, it is important to appreciate that oral inhaled
product dissolution methods are at an early stage of
development and are not optimised for in vitro-in vivo
correlation. Furthermore, PK-PD relationships to link
the potency of inhaled drugs, physicochemical
properties, drug formulation, dose interval, temporal
profiles of free (unbound) drug concentration at the ef-
fect site and pharmacological response are at a nascent
stage of development (43, 44).
Using more physiological conditions for in vitro investiga-
tions into inhalation biopharmaceutics may improve the ac-
curacy of physiologically-based mechanistic modeling and in
the future biorelevence may be extended to reflect any differ-
ences in RTLF in lung disease and the influence of less abun-
dant components that are recognized to have functional sig-
nificance, e.g. surfactant proteins that are concentrated in the
corona that forms on the surface of biopersistent nanoparticles
and influences their uptake [45,46].
CONCLUSIONS
We report a synthetic simulated lung fluid based on
human RTLF that can be used for the in vitro studies
Fig. 3 Whole human genome microarray analysis of A549 cells incubated for 24 h with simulated lung fluid (SLF) or standard tissue culture media. Panel (a) -
Volcano plot: All 116 significantly differentially expressed (DE) genes are displayed according to their measured expression change (x-axis) and negative log (base
10) of the p-value (y-axis). The higher the gene is plotted on the y-axis, the more significant it is. The dotted line shows the thresholds for expression change;
p < 0.05. The top 20 up and down regulated genes, reflecting the highlighted section in panel A are provided in panel (b). Panel (c) - Pathways perturbation
vs over-representation: The most disrupted pathways are plotted in terms of the two types of evidence: over-representation on the x-axis (pORA) and the
total perturbation accumulation on the y-axis (pAcc). Red spots indicate significantly perturbed pathways, with the size of the spot reflecting the number of DE
genes within the identified pathways. Panel (d) illustrates the DE genes within the three most significant pathways identified as perturbed following incubation with
the SLF.
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into inhalation biopharmaceutics, e.g. the solubility of
inhaled drugs, dissolution of aerosol particles and
particle-lung cell interactions. The SLF has a stable col-
loidal structure, possessing vesicles that are similar in
nature to those found in lung extracts. No adverse ef-
fects on A549 cells were observed after exposure to the
simulant for 24 h, although some metabolic changes
were indicated that are consistent with the change of
culture medium to a more physiologic composition.
Based on preliminary results, we hypothesize that the
use of biorelevant medium provides realistic estimates
of the solubility and dissolution of hydrophobic drugs
in vivo. Whilst the present SLF was based on the com-
position of RTLF from the alveolar region of healthy
subjects, we acknowledge that further work is still re-
quired to develop simulants reflective of different re-
gions of the airway, as well as variation in composition
associated with established respiratory disease.
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Fig. 4 (a) Solubility.
Beclomethasone dipropionate
(BDP) and fluticasone propionate
(FP) solubility in media used to
represent lung fluid: Gamble’s
solution, the biorelevant simulated
lung fluid, SLF, Survanta® and 0.5%
SDS. (b) Dissolution of BDP.
Aerosol from QVAR® 50 μg
pressurised metered dose inhalers,
(c) Dissolution of FP. Aerosol
from Flixotide® 50 μg pressurised
metered dose inhalers. Data
represent mean ± sd, n = 3.
Kumar et al.
ACKNOWLEDGEMENTS AND DISCLOSURES
This research received support from the QualityNano project
http://www.qualitynano.eu which is financed by the
European Community Research Infrastructures under the
FP7 Capacities Programme (Grant No. INFRA-2010-
262,163), and its partners VITO (for transcriptomics) and
Uppsala University (for CryoTEM). Elif Melis Bicer was
supported by a BBSRC-CASE studentship (BB/1532696/1)
in association with GlaxoSmithKline Research &
Development. Mireille Hassoun was supported by a
BBSRC-CASE studentship (BB/K012762/1), in association
with Intertek-Melbourn.
OpenAccessThis article is distributed under the terms of the
Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which per-
mits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
REFERENCES
1. Bäckman P, Adelmann H, Petersson G, Jones CB. Advances in
inhaled Technologies: understanding the therapeutic challenge,
predicting clinical performance, and designing the optimal inhaled
product. Clin Pharmacol Ther. 2014;95:509–20.
2. Borghardt JM, Weber B, Staab A, Kloft C. Pharmacometric
models for characterizing the pharmacokinetics of orally inhaled
drugs. AAPS J. 2015;17:853–70.
3. Edsbacker S, Wollmer P, Selroos O, Borgstrom L, Olsson B, Ingelf
J. Do airway clearance mechanisms influence the local and systemic
effects of inhaled corticosteroids? Pulm Pharmacol Ther. 2008;21:
247–58.
4. Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, Kim K-J,
et al. The particle has landed–characterizing the fate of inhaled
pharmaceuticals . J . Aerosol Med. Pulm. Drug Deliv.
2010;23(Suppl 2):S71–87.
5. Foster WM, Langenback E, Bergofsky EH. Measurement of tra-
cheal and bronchial mucus velocities in man : relation to lung clear-
ance. J Appl Physiol. 1980;48:965–71.
6. StöberWKW. A simple pulmonary retentionmodel accounting for
dissolution and macrophage-mediated removal of deposited poly-
disperse particles. Inhal. Toxicol. 2001;13:129–48.
7. Jones RM, Neef N. Interpretation and prediction of inhaled drug
particle accumulation in the lung and its associated toxicity.
Xenobiotica. 2012;42:86–93.
8. Forbes B,O’LoneR, Allen PP, Cahn A, Clarke C, CollingeM, et al.
Challenges for inhaled drug discovery and development: Induced
alveolar macrophage responses. Adv. Drug Deliv. Rev. Elsevier
B.V. 2014;71:15–33.
9. Hastedt JE, Bäckman P, Clark AR, Doub W, Hickey A, Hochhaus
G, et al. Scope and relevance of a pulmonary biopharmaceutical
classification system AAPS/FDA/USP workshop march 16-17th,
2015 in Baltimore. MD AAPS Open AAPS Open. 2016;2:1–20.
10. Lennernäs H, Aarons L, Augustijns P, Beato S, Bolger M, Box K,
et al. Oral biopharmaceutics tools - time for a new initiative - an
introduction to the IMI project OrBiTo. Eur J Pharm Sci. 2014;57:
292–9.
11. Augustijns P, Wuyts B, Hens B, Annaert P, Butler J, Brouwers J,
et al. Eur. J. Pharm. Sci. Elsevier B.V. 2014;57:322–32.
12. Riethorst D, Baatsen P, Remijn C, Mitra A, Tack J, Brouwers J,
et al. An in-depth view into human intestinal fluid colloids: inter-
subject variability in relation to composition. Mol. Pharm. 2016;13:
3484–93.
13. Wuyts B, Riethorst D, Brouwers J, Tack J, Annaert P, Augustijns P.
Evaluation of fasted and fed state simulated and human intestinal
fluids as solvent system in the Ussing chambers model to explore
food effects on intestinal permeability. Int. J. Pharm. Elsevier B.V.
2015;478:736–44.
14. Marques MRC, Loebenberg R, Almukainzi M. Simulated biolog-
ical fluids with possible application in dissolution testing.
Dissolution Technol. 2011;18:15–28.
15. Patel N, Forbes B, Eskola S, Murray J. Use of simulated intestinal
fluids with Caco-2 cells and rat ileum. Drug Dev Ind Pharm.
2006;32:151–61.
16. Klein S. The use of biorelevant dissolution media to forecast the
in vivo performance of a drug. AAPS J. 2010;12:397–406.
17. Arora D, Shah KA, Halquist MS, Sakagami M. In vitro aqueous
fluid-capacity-limited dissolution testing of respirable aerosol drug
particles generated from inhaler products. Pharm Res. 2010;27:
786–95.
18. Davies NM, Feddah MR. A novel method for assessing dissolution
of aerosol inhaler products. Int J Pharm. 2003;255:175–87.
19. Son YJ, McConville JT. Development of a standardized dissolution
test method for inhaled pharmaceutical formulations. Int J Pharm.
2009;382:15–22.
20. May S, Jensen B, Weiler C, Wolkenhauer M, Schneider M, Lehr
CM. Dissolution testing of powders for inhalation: influence of par-
ticle deposition and modeling of dissolution profiles. Pharm Res.
2014;31:3211–24.
21. Buttini F, Miozzi M, Balducci AG, Royall PG, Brambilla G,
Colombo P, et al. Differences in physical chemistry and dissolution
rate of solid particle aerosols from solution pressurised inhalers. Int.
J. Pharm. Elsevier B.V. 2014;465:42–51.
22. Rohrschneider M, Bhagwat S, Krampe R, Michler V, Breitkreutz
J, Hochhaus G. Evaluation of the Transwell system for characteri-
zation of dissolution behavior of inhalation drugs: effects of mem-
brane and surfactant. Mol Pharm. 2015;12:2618–24.
23. Pham S, Wiedmann TS. Dissolution of aerosol particles of
budesonide in Survanta, a model lung surfactant. J Pharm Sci.
2001;90:98–104.
24. Bicer EM. Compositional characterisation of human respiratory
tract lining fluids for the design of disease specific simulants.
King’s College London 2015.
25. Kumar A, Bicer EM, Morgan AB, Pfeffer PE, Monopoli M,
Dawson KA, et al. Enrichment of immunoregulatory proteins in
the biomolecular corona of nanoparticles within human respiratory
tract lining fluid. Nanomed Nanotechnol Biol. Med. Elsevier B.V.
2016;12:1033–43.
26. Scarpelli EM, Gabbay KH, Kochen JA. Lung surfactants,
Counterions, and hysteresis. Science. 1965;148:1607–9.
27. Vollhardt D, Fainerman VB. Progress in characterization of
Langmuir monolayers by consideration of compressibility. Adv
Colloid Interf Sci. 2006;127:83–97.
28. Choi Y, Attwood SJ, Hoopes MI, Drolle E, Karttunen M,
Leonenko Z. Melatonin directly interacts with cholesterol and alle-
viates cholesterol effects in dipalmitoylphosphatidylcholine mono-
layers. Soft Matter. 2014;10:206–13.
29. Dynarowicz-Łatka P, Hac-Wydro K. Interactions between phos-
phatidylcholines and cholesterol in monolayers at the air/water
interface. Colloids Surfaces B Biointerfaces. 2004;37:21–5.
A Biocompatible Synthetic Lung Fluid
30. Grainger CI, Saunders M, Buttini F, Telford R, Merolla LL,
Martin GP, et al. Critical characteristics for corticosteroid solution
metered dose inhaler bioequivalence. Mol Pharm. 2012;9:563–9.
31. Filipe V, Hawe A, Jiskoot W. Critical evaluation of nano-
particle tracking analysis (NTA) by NanoSight for the mea-
surement of nanoparticles and protein aggregates. Pharm
Res. 2010;27:796–810.
32. Lee KYC, Gopal A, von Nahmen A, Zasadzinski JA, Majewski J,
Smith GS, et al. Influence of palmitic acid and hexadecanol on the
phase transition temperature and molecular packing of
dipalmitoylphosphatidyl-choline monolayers at the air–water inter-
face. J Chem Phys. 2002;116:774.
33. Pérez-Gil J, Keough KMW. Interfacial properties of surfactant
proteins. Biochim. Biophys. Acta - Mol. Basis Dis. 1998;1408:
203–17.
34. Antal JM, Divis LT, Erzurum SC, Wiedemann HP, Thomassen
MJ. Surfactant suppresses NF-KB activation in human Monocytic
cells. Am J Respir Cell Mol Biol. 1996;14:374–9.
35. Morris RHK, Tonks AJ, Jones KP, Ahluwalia MK, Thomas AW,
Tonks A, et al. DPPC regulates COX-2 expression inmonocytes via
phosphorylation of CREB. Biochem Biophys Res Commun.
2008;370:174–8.
36. Tokumura T, Miyazaki E, Isaka H, Kaneko N, Kanou M.
Solubility of fluticasone propionate in aqueous solutions measured
by a method avoiding its adsorption to experimental tools. Int Res J
Pharm Appl Sci. 2014;4:19–24.
37. Sahib MN, Abdalwahed S, Abdulameer DY, Peh KK, YTF T.
Solubilization of beclomethasone dipropionate in sterically stabi-
lized phospholipid nanomicelles (SSMs): Physicochemical and
in vitro evaluations. Drug Des. Devel. Ther. 2012;6:29–42.
38. Wiedmann TS, Bhatia R, Wattenberg LW. Drug solubilization in
lung surfactant. J Control Release. 2000;65:43–7.
39. Liao X, Wiedmann TS. Solubilization of cationic drugs in lung
surfactant. Pharm Res. 2003;20:1858–63.
40. Kim K, Choi SQ, Zell ZA, Squires TM, Zasadzinski JA. Effect of
cholesterol nanodomains onmonolayer morphology and dynamics.
Proc Natl Acad Sci U S A. 2013;110:E3054–60.
41. Kim SH. Adsorption and interactions of lung surfactant lipids and
proteins at air/aqueous interfaces and in aqueous solution. Purdue
University; 2007.
42. Das SC, Stewart PJ. The influence of lung surfactant liquid crystal-
line nanostructures on respiratory drug delivery. Int J Pharm.
2016;514:465–74.
43. Boger E, Evans N, Chappell M, Lundqvist A, Ewing P,
Wigenborg A, et al. Systems pharmacology approach for
prediction of pulmonary and systemic pharmacokinetics and
receptor occupancy of inhaled drugs. CPT Pharmacometrics
Syst Pharmacol. 2016;5:201–10.
44. Cooper AE, Ferguson D, Grime K. Optimisation of DMPK by the
inhaled route: challenges and approaches. Curr Drug Metab.
2012;13:457–73.
45. Shaw CA, Mortimer GM, Deng ZJ, Carter ES, Connell SP,
Miller MR, Duffin R, Newby DE, Hadoke PWF, Minchin
RF. Prote in corona format ion in bronchoalveolar
fluidenhances diesel exhaust nanoparticle uptake and pro-
inflammatory responses in macrophages. Nanotoxicology.
2016;10:981–91.
46. Wohlleben W, Driessen MD, Raesch S, Schaefer UF,
Schulze C, von Vacano B, Vennemann A, Wiemann M,
Ruge CA, Platsch H, Mues S, Ossig R, Tomm JM,
Schnekenburger J, Kuhlbusch TAJ, Luch A, Lehr C-M,
Haase A. Influence of agglomeration and specific lung lining
lipid/protein interaction on short-term inhalation toxicity.
Nanotoxicology. 2016;10:970–80.
Kumar et al.
